Safety Study of TAK-700 in Subjects With Prostate Cancer.
(TAK-700 Trial)
Recruiting in Palo Alto (17 mi)
+18 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Millennium Pharmaceuticals, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
Research Team
MM
Medical Monitor
Principal Investigator
Millennium Pharmaceuticals, Inc.
Eligibility Criteria
Inclusion Criteria
Subject is male and at least 18 years of age.
Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.
Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.
See 7 more
Treatment Details
Interventions
- TAK-700 (Anti-androgen)
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Arm 4 (TAK-700 at 600 mg)Experimental Treatment1 Intervention
Group II: Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)Experimental Treatment1 Intervention
Group III: Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)Experimental Treatment1 Intervention
Group IV: Arm 1 (TAK-700)Experimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Southern CaliforniaLos Angeles, CA
Kellogg Cancer Care CenterGlenview, IL
Taussig Cancer InstituteCleveland, OH
Cleveland ClinicCleveland, OH
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Millennium Pharmaceuticals, Inc.
Lead Sponsor
Trials
406
Patients Recruited
46,900+